Search
SRP 299
go.drugbank.com/drugs/DB05440ExperimentalMycobacterium vaccae is a non-pathogenic, saprophytic bacteria whose antigens can be used to induce peripheral immune activation through the activity of regulatory T-cells that surpress inappropriate Th2 … A specific subset of serotonergic neurons in the interfascicular part of the dorsal raphe nucleus (DRI) is believed to be involved, based on studies with mice.
Phelimin
go.drugbank.com/drugs/DB18332Experimental[L48151] It is under investigation for the treatment of hyperphenylalaninemia. … Phelemin (PHE-MIP) is a methacrylic acid-based copolymer purified to bind to L-phenylalanine and L-phenylalanine-containing peptides.
Prednisolone sodium metazoate
go.drugbank.com/drugs/DB05340InvestigationalReleasing the drug directly into the colon reduces the potential for significant side effects often experienced with steroid drugs. Colal-Pred is being studied for use in ulcerative colitis.
Becocalcidiol
go.drugbank.com/drugs/DB04891InvestigationalBecocalcidiol is a vitamin D(3) analogue which has not caused hypercalcaemia or significant irritation in preclinical trials.
OSI-930
go.drugbank.com/drugs/DB05913InvestigationalOSI-930 is designed to target both cancer cell proliferation and blood vessel growth (angiogenesis) in selected tumors. … OSI-930 is an orally active inhibitor of two clinically validated targets: c-Kit and the vascular endothelial growth factor receptor-2 (VEGFR-2).
HMR4011
go.drugbank.com/drugs/DB06225ExperimentalIPL 576,092 has previously been investigated as a treatment for asthma.
Santonin
go.drugbank.com/drugs/DB19377ApprovedWithdrawnSantonin is a anthelmintic drug that was previously approved in the US to treat certain parasitic infections.
Cobalt Co-60
go.drugbank.com/drugs/DB15374ExperimentalCobalt Co-60 is under investigation in clinical trial NCT02891083 (Adjuvant Therapies or Surgery Alone for High Risk pN0 Esophageal Cancer).
AZD7442
go.drugbank.com/drugs/DB15787InvestigationalAZD7442 is a combination of SARS-CoV-2 antibodies (AZD8895 + AZD1061) currently undergoing phase I clinical trials for the prevention and treatment of COVID-19. … [L15596] It was developed by AstraZeneca with the goal of conferring at least 6 months of protection against COVID-19 - a significantly longer window of efficacy than that of other vaccines.[L15591]
Categories: Experimental Unapproved Treatments for COVID-19AM336
go.drugbank.com/drugs/DB06563ExperimentalLeconotide (development codes CNSB004 and AM336) is an omega-conotoxin peptide known for its analgesic properties, which work by blocking neuronal voltage-sensitive calcium channels. … It was investigated as a potential treatment for various pain conditions.